The National Hospital, Abuja, has confirmed the deaths of two adult patients following serious adverse events suspected to be linked to the administration of Fortcef Injection (Ceftazidime).
The development was contained in an internal memo dated September 10, 2026, signed by the hospital’s Director of Clinical Services and Chairman of the Medical Advisory Committee, Dr O. Lawal.
According to the memo, the two patients were reportedly relatively stable before receiving the drug. Following the incidents, the hospital’s Pharmacovigilance Committee identified the cases and directed clinical units to increase surveillance of Ceftazidime sourced from outside the hospital.
The drug identified in connection with the cases is Fortcef Injection 1g, with batch number PEZIE001. The batch was manufactured in May 2025 and has an expiry date of April 2028. Its NAFDAC registration number is C4-0247.
Related News:
Abuja Hospital Denies Involvement in Alleged Kidney Trafficking, Suspends Transplant Services
Adamawa Hospital Cleaner Arrested for Stealing Corps Member’s ₦18m Car
Mary Habila Buried in Kaduna as Questions Over Death, Autopsy Remain Unresolved
The hospital said the cases had been reported to the National Agency for Food and Drug Administration and Control (NAFDAC) for further investigation.
Medical personnel were also instructed to promptly report any suspected adverse reactions associated with Ceftazidime to the hospital’s Pharmacovigilance Committee.
The confirmation comes amid a viral voice note purportedly recorded by a nurse, which had alleged that four deaths occurred after patients were administered Fortcef. However, the hospital’s internal memo specifically documented serious adverse events involving two adult patients, rather than four.
The reported cases are now subject to pharmacovigilance investigation as authorities work to establish the circumstances surrounding the adverse events.
About the Author
